Abstract
The enzyme phospholipase A2 catalyzes the cleavage of the sn-2 acyl ester bond of phospholipids, leading to the production of free fatty acids and lysophospholipids, which leads to many inflammatory disorders. In view of its pharmaceutical interest, three phospholipase A2 + inhibitor (namely, (i) L-1-O-octyl-2-heptylphosphonyl-sn-glycero-3- phosphoethanolamine, Transition State Analogue, (ii) 1-Hexadecyl-3-(trifluoroethyl)-sn-glycero-2-phosphomethanol, MJ33 and (iii) p-methoxybenzoic acid, anisic acid) complex structures have already been solved and analysed, using the data obtained from X-ray diffraction. These structures provide insight on the mode of binding of the inhibitor molecules at the active site of phospholipase A2. The knowledge of the active site geometry in these inhibitor bound structures, yield valuable information in the design of more useful therapeutic agents. This report reviews only the inhibitor bound recombinant bovine pancreatic phospholipase A2 structures solved using X-ray crystallography.
Keywords: X-ray crystallography, phospholipase A2, extra cellular, drug/inhibitor molecules, surface loop, inflammation and rheumatoid arthritis
Current Topics in Medicinal Chemistry
Title: Structural Biology of Recombinant Bovine Pancreatic Phospholipase A2 and its Inhibitor Complexes
Volume: 7 Issue: 8
Author(s): K. Sekar
Affiliation:
Keywords: X-ray crystallography, phospholipase A2, extra cellular, drug/inhibitor molecules, surface loop, inflammation and rheumatoid arthritis
Abstract: The enzyme phospholipase A2 catalyzes the cleavage of the sn-2 acyl ester bond of phospholipids, leading to the production of free fatty acids and lysophospholipids, which leads to many inflammatory disorders. In view of its pharmaceutical interest, three phospholipase A2 + inhibitor (namely, (i) L-1-O-octyl-2-heptylphosphonyl-sn-glycero-3- phosphoethanolamine, Transition State Analogue, (ii) 1-Hexadecyl-3-(trifluoroethyl)-sn-glycero-2-phosphomethanol, MJ33 and (iii) p-methoxybenzoic acid, anisic acid) complex structures have already been solved and analysed, using the data obtained from X-ray diffraction. These structures provide insight on the mode of binding of the inhibitor molecules at the active site of phospholipase A2. The knowledge of the active site geometry in these inhibitor bound structures, yield valuable information in the design of more useful therapeutic agents. This report reviews only the inhibitor bound recombinant bovine pancreatic phospholipase A2 structures solved using X-ray crystallography.
Export Options
About this article
Cite this article as:
Sekar K., Structural Biology of Recombinant Bovine Pancreatic Phospholipase A2 and its Inhibitor Complexes, Current Topics in Medicinal Chemistry 2007; 7 (8) . https://dx.doi.org/10.2174/156802607780487632
DOI https://dx.doi.org/10.2174/156802607780487632 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy S1P Regulation of Macrophage Functions in the Context of Cancer
Anti-Cancer Agents in Medicinal Chemistry Suppressive Effects of the Standardized Extract of Phyllanthus amarus on Type II Collagen-induced Rheumatoid Arthritis in Sprague Dawley Rats
Current Pharmaceutical Biotechnology Recent Advances in Hematopoietic Stem Cell-Mediated Regeneration
Recent Patents on Regenerative Medicine Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives
Current Medicinal Chemistry Use of Thiazolidinediones and Risk of Bladder Cancer: Disease or Drugs?
Current Drug Safety Is Metabolic Syndrome X a Disorder of the Brain?
Current Nutrition & Food Science From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology
Current Medicinal Chemistry Selenium Compounds and Apoptotic Modulation: A New Perspective in Cancer Therapy
Mini-Reviews in Medicinal Chemistry Discrepancies in Animal Models of Preterm Birth
Current Pharmaceutical Design Medications Affecting Functional Status in Older Persons
Current Pharmaceutical Design Allergen-Specific Responses of CD19high and CD19low B Cells in Non-IgEMediated Food Allergy of Late Eczematous Reactions in Atopic Dermatitis: Presence of IL-17- and IL-32-Producing Regulatory B Cells (Br17 & Br32)
Inflammation & Allergy - Drug Targets (Discontinued) New Cell Therapy Using Bone Marrow-Derived Stem Cells/Endothelial Progenitor Cells to Accelerate Neovascularization in Healing of Experimental Ulcerative Colitis
Current Pharmaceutical Design AICD Nuclear Signaling and Its Possible Contribution to Alzheimers Disease
Current Alzheimer Research Function of miRNA in Controlling Drug Resistance of Human Cancers
Current Drug Targets Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Enhancing Transdermal Drug Delivery with Electroporation
Recent Patents on Drug Delivery & Formulation CIITA and the MHCII Enhanceosome in the Regulation of MHCII Expression
Current Genomics Focus on Immunology of Trichinellosis
Medicinal Chemistry Reviews - Online (Discontinued)